A review of sitaxsentan sodium in patients with pulmonary arterial hypertension

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 151-157

  Waxman, Aaron B ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Endothelin; Endothelin A; Endothelin receptor antagonist; Endothelin receptor inhibitor; Pulmonary hypertension; Sitaxsentan

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; SITAXSENTAN; WARFARIN;

BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; EPISTAXIS; EXERCISE; FATALITY; FATIGUE; HEART RIGHT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; INCIDENCE; INSOMNIA; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TOXICITY; META ANALYSIS; NAUSEA; NOSE CONGESTION; PERIPHERAL EDEMA; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TERATOGENICITY; TISSUE LEVEL;

CLINICAL TRIALS; HUMANS; HYPERTENSION, PULMONARY; ISOXAZOLES; PULMONARY WEDGE PRESSURE; RECEPTORS, ENDOTHELIN; THIOPHENES; TREATMENT OUTCOME;

EID: 34249848933     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Abbott SD, Fagan-Smith E, Coyne TC 2006. Background Incidence of Elevated Liver Aminotransferases in Pulmonary Arterial Hypertension PAH.: Results from 4 Placebo-Controlled Clinical Trials. Proceedings of the American Thoracic Society 2006 International Conference. San Diego, CA.
2. Actellion Tracleer® bosentan. 2004. Prescribing information [online]. Updated August 2004; Last accessed 8 December 2004. URL: http://www.tracleer.com/TRALibrary/TRALib004/ TRALib004PrescribingInfo.html.
3. Barst RJ. 2001. Medical therapy of pulmonary hypertension. An overview of treatment and goals. Clin Chest Med, 22:509-15, ix.
4. Barst RJ, Langleben D, Badesch D, et al; O. B. O. T. S.-S. 2006. Treatment of pulmonary arterial hypertension with the selective endothelin - a receptor antagonist sitaxsentan. J Am Coll Cardiol, 47:2049-56.
5. Barst RJ, Langleben D, Frost A, et al. 2004. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 169:441-7.
6. Barst RJ, Rich S, Widlitz A, et al. 2002. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension:open-label pilot study. Chest, 121:1860-8.
7. Barst RJ, Rubin LJ, Long WA, et al. 1996. A comparison of continuous intravenous epoprostenol prostacyclin. with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med, 334:296-302.
8. Behr J, Borst MM, Winkler J, et al. 2005. (A role for combination therapy in pulmonary arterial hypertension]. Pneumologie, 59:730-5.
9. Benigni A, Remuzzi G. 1999. Endothelin antagonists. Lancet, 353:133-8.
10. Channick RN, Simonneau G, Sitbon, et al. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension:a randomised placebo-controlled study. Lancet, 358:1119-23.
11. Coyne TC, Dixon RA. 2005. Warfarin management in pulmonary arterial hypertension is similar between bosentan, placebo, and sitaxsentan. Chest, 128:366S.
12. Coyne TC, Garces PC, Dixon RA. 2006. Warfarin Management and Bleeding with Sitaxsentan and Bosentan. Proceedings of the American Thoracic Society 2006 International Conference. San Diego, CA.
13. Davenport AP, Battistini B. 2002. Classification of endothelin receptors and antagonists in clinical development. Clin Sci Lond, 103(Suppl 48):1S-3S.
14. Dingemanse J, Van Giersbergen PL. 2004. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet, 43:1089-115.
15. Frost AE, Langleben D, Oudiz R, et al. 2005. The 6-min walk test 6MW. as an efficacy endpoint in pulmonary arterial hypertension clinical trials:demonstration of a ceiling effect. Vascul Pharmacol, 43:36-9.
16. Giaid A, Yanagisawa M, Langleben D, et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med, 328:1732-9.
17. Girgis RE, Mathai SC, Krishnan JA, et al. 2005. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant, 24:1626-31.
18. Horn EM, Langleben D, Frost A. 2004. Chronic sitaxsentan in pulmonary arterial hypertension. Am J Respir Crit Care Med, 169:A210.
19. Langleben D, Brock T, Dixon R, et al. 2004a. STRIDE 1:Effects of the selective ETA receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials. J Cardiovasc Pharmacol, 44:S80-S84.
20. Langleben D, Dupuis J, Langleben I, et al. 2006. Etiology-specific endothelin-1 clearance in human precapillary pulmonary hypertension. Chest, 129:689-95.
21. Langleben D, Hirsch AM, Shalit E, et al. 2004b. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension:a 1-year follow-up study. Chest, 126:1377-81.
22. Langleben D, Hirsch AM, Shalit E, et al. 2005. Sustained efficacy with the highly selective orally-active endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension. Proceedings of the American Thoracic Society 2005 International Conference. San Diego, CA.
23. Mclaughlin VV, Shillington A, Rich S. 2002. Survival in primary pulmonary hypertension:the impact of epoprostenol therapy. Circulation, 106:1477-82.
24. Mclaughlin VV Sitbon O, Badesch DB, et al. 2005. Survival with firstline bosentan in patients with primary pulmonary hypertension. Eur Respir J, 25:244-9.
25. Miyamoto S, Nagaya N, Satoh T, et al. 2000. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med, 161:487-92.
26. Oudiz R, Badesch D, Girgis RE, et al. 2006a. Functional class improvement with sitaxsentan in patients with Class II-IV pulmonary arterial hypertension PAH. Proceedings of the American Thoracic Society 2006 International Conference. San Diego, CA.
27. Oudiz RJ, Barst RJ, Hansen JE, et al. 2006b. Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension. Am J Cardiol, 97:123-6.
28. Rich S. 1998. Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France: World Health Organization.
29. Rich S, Dantzker DR, Ayres SM, et al. 1987. Primary pulmonary hypertension. A national prospective study. Ann Intern Med, 107:216-23.
30. Rubens C, Ewert R, Halank M, et al. 2001. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest, 120:1562-9.
31. Rubin LJ, Badesch DB, Barst RJ, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med, 346:896-903.
32. Sitbon O, Humbert M, Nunes H, et al. 2002. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension:prognostic factors and survival. J Am Coll Cardiol, 40:780-8.
33. Tilton RG, Munsch CL, Sherwood SJ, et al. 2000. Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ETA. receptor antagonist. Pulm Pharmacol Ther, 13:87-97.
34. Wu C, Chan MF, Stavros F, et al. 1997. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem, 40:1690-7.
35. Wu C, Decker ER, Blok N, et al. 1999. Endothelin antagonists:substituted mesitylcarboxamides with high potency and selectivity for ETA. receptors. J Med Chem, 42:4485-99.